The two biotech stocks highlighted in today’s article await big FDA decisions this month – one for an anti-itch drug that could be used in a variety of health conditions and the other for a broad-based anti-cancer agent. More importantly, Wall Street sees both of these names as solid Buys ahead of these pivotal FDA decisions. For these two biotech stocks, and more on their respective product candidates and analyst expectations for them, CLICK HERE.
Ahead Of Big FDA Decisions On Their Anti-Itch And Anti-Cancer Drugs, Analysts See These 2 Biotech Stocks As Solid Buys
- by RobH